R. Zheng

发表

Taking Quinazoline as a General Support‐Nog to Design Potent and Selective Kinase Inhibitors: Application to FMS‐like Tyrosine Kinase 3

Li Yang, Yu-Quan Wei, Xiao-Yu Qing, 2010, ChemMedChem.

SKLB610: A Novel Potential Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibits Angiogenesis and Tumor Growth in Vivo

Shi-Dong Luo, Yuquan Wei, Sheng-yong Yang, 2011, Cellular Physiology and Biochemistry.

Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor

Ze-Rong Wang, Lin-Li Li, Sheng-yong Yang, 2014, Molecular Diversity.

SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants

L. Zhong, R. Zheng, Z. Cao, 2012, Leukemia.

Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.

Yong Xu, Shan Feng, L. Zhong, 2012, Journal of medicinal chemistry.

Small molecular anticancer agent SKLB703 induces apoptosis in human hepatocellular carcinoma cells via the mitochondrial apoptotic pathway invitro and inhibits tumor growth invivo.

Luoting Yu, Yan Zhou, Hong-jun Lin, 2011, Cancer letters.

Novel thienopyridine derivatives as specific anti-hepatocellular carcinoma (HCC) agents: synthesis, preliminary structure-activity relationships, and in vitro biological evaluation.

Jiyan Liu, Yuquan Wei, Sheng-yong Yang, 2010, Bioorganic & medicinal chemistry letters.

Facile Synthesis of 6-Aryl-3-cyanopyridine-2-(1H)-thiones from Aryl Ketones

Luoting Yu, Shengyong Yang, J. He, 2012 .

SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo

Yuquan Wei, Xia Zhao, Wei Wang, 2011, Clinical Cancer Research.

Cancer Therapy : Preclinical SKLB 1002 , a Novel Potent Inhibitor of VEGF Receptor 2 Signaling , Inhibits Angiogenesis and Tumor Growth In Vivo

Yuquan Wei, Xia Zhao, Wei Wang, 2011 .

Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.

Yu-Quan Wei, Yong Xu, Ren-Lin Zheng, 2012, Journal of medicinal chemistry.

SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo

Yong Xu, Yang Yu, Xin Chen, 2012, Molecular Cancer Therapeutics.

Preclinical Development SKLB 1206 , a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T 790 M Mutants , ErbB 2 , ErbB 4 , and VEGFR 2 , Displays Potent Antitumor Activity Both In Vitro and In Vivo

Shan Feng, Shi-Dong Luo, You-Li Pan, 2012 .

SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy.

G. Shen, X. Chen, H. Deng, 2012, Neoplasma.

Pharmacophore Modeling and Hybrid Virtual Screening for the Discovery of Novel IκB Kinase 2 (IKK2) Inhibitors

Ji-Xia Ren, Huan-Zhang Xie, Ren-Lin Zheng, 2011, Journal of biomolecular structure & dynamics.

Discovery of Novel Pim-1 Kinase Inhibitors by a Hierarchical Multistage Virtual Screening Approach Based on SVM Model, Pharmacophore, and Molecular Docking

Xin Chen, Lin-Li Li, Sheng-Yong Yang, 2011, J. Chem. Inf. Model..

Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor

Ze-Rong Wang, Lin-Li Li, Sheng-yong Yang, 2014, Molecular Diversity.

4-(4-Nitrobenzyl)morpholine

Ling-Ling Yang, R. Zheng, Guo-Bo Li, 2011, Acta crystallographica. Section E, Structure reports online.

Novel thienopyridine derivatives as specific anti-hepatocellular carcinoma (HCC) agents: synthesis, preliminary structure-activity relationships, and in vitro biological evaluation.

Jiyan Liu, Yuquan Wei, Sheng-yong Yang, 2010, Bioorganic & medicinal chemistry letters.